Skip to content
Nonprofiteer
← GABRIELLES ANGEL FOUNDATION FOR CANCER RESEARCH INC

Form 990 for tax year 2023

Filed by GABRIELLES ANGEL FOUNDATION FOR CANCER RESEARCH INC.

Totals

Total revenue
$3,625,026
Total expenses
$3,622,772
Contributions and grants received
$3,504,879
Grants paid
$2,703,500
Program service revenue
$0
Investment income
$256,284
Other revenue
-$136,137
Total assets, end of year
$6,114,423
Total liabilities, end of year
$4,403,588
Net assets or fund balances, end of year
$1,710,835
Program services expenses (Part IX)
$3,284,192
Management and general expenses
$173,781
Fundraising expenses
$164,799
Program service expenses (Part III)
$3,284,192

Program services were 90.7% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1c · Fundraising events

    $2,557,294

  • 1f · All other contributions, gifts and grants

    $947,585

  • 3 · Investment income

    total $179,890 · excluded $179,890

  • 7a · Gross sales of assets other than inventory

    securities $665,773

  • 7b · Less cost or other basis and sales expenses

    securities $589,379

  • 7c · Gain or loss

    securities $76,394

  • 7d · Net gain or loss

    total $76,394 · excluded $76,394

  • 8a · Fundraising events: gross income

    $857,494

  • 8a · Fundraising events: contributions included on line 1c

    $2,557,294

  • 8b · Fundraising events: direct expenses

    $1,040,160

  • 8c · Net income from fundraising events

    total -$182,666 · excluded -$182,666

  • 11a · Other revenue: OTHER INCOME

    total $46,529 · related or exempt $46,529

  • 11e · Other revenue, total

    $46,529

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $2,703,500 · program services $2,703,500

  • 5 · Compensation of officers, directors and key employees

    total $197,776 · program services $139,516 · management and general $34,399 · fundraising $23,861

  • 7 · Other salaries and wages

    total $179,158 · program services $126,383 · management and general $31,160 · fundraising $21,615

  • 8 · Pension plan contributions

    total $13,052 · program services $9,216 · management and general $2,253 · fundraising $1,583

  • 9 · Other employee benefits

    total $69,059 · program services $48,761 · management and general $11,922 · fundraising $8,376

  • 10 · Payroll taxes

    total $26,598 · program services $18,780 · management and general $4,592 · fundraising $3,226

  • 11b · Fees: legal

    total $1,750 · management and general $1,750

  • 11c · Fees: accounting

    total $36,854 · management and general $36,854

  • 11f · Fees: investment management

    total $230 · management and general $230

  • 11g · Fees: other

    total $195,337 · program services $110,168 · management and general $2,353 · fundraising $82,816

  • 13 · Office expenses

    total $52,192 · program services $26,103 · management and general $19,796 · fundraising $6,293

  • 14 · Information technology

    total $1,569 · program services $1,098 · fundraising $471

  • 16 · Occupancy

    total $36,000 · program services $25,409 · management and general $6,221 · fundraising $4,370

  • 17 · Travel

    total $6,403 · program services $2,240 · management and general $3,458 · fundraising $705

  • 23 · Insurance

    total $7,004 · program services $4,944 · management and general $1,210 · fundraising $850

  • 24a · Other expenses: CONFERENCE AND MEDICAL

    total $35,511 · program services $35,511

  • 24b · Other expenses: OTHER

    total $35,108 · program services $23,322 · management and general $7,571 · fundraising $4,215

  • 24c · Other expenses: PUBLIC RELATIONS & PROM

    total $25,671 · program services $9,241 · management and general $10,012 · fundraising $6,418

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $227,767 · end of year $196,240

  • 2 · Savings and temporary cash investments

    beginning of year $1,477,916 · end of year $1,815,023

  • 3 · Pledges and grants receivable

    beginning of year $592,814 · end of year $743,027

  • 9 · Prepaid expenses and deferred charges

    beginning of year $58,784 · end of year $58,784

  • 11 · Investments: publicly traded securities

    beginning of year $2,775,256 · end of year $3,293,269

  • 15 · Other assets

    beginning of year $1,411 · end of year $8,080

  • 17 · Accounts payable and accrued expenses

    beginning of year $31,159 · end of year $38,588

  • 18 · Grants payable

    beginning of year $3,733,000 · end of year $4,365,000

  • 27 · Net assets without donor restrictions

    beginning of year $944,385 · end of year $992,096

  • 28 · Net assets with donor restrictions

    beginning of year $425,404 · end of year $718,739

Mission and programs · 2023

Mission

THE PURPOSE OF GABRIELLE'S ANGEL FOUNDATION FOR CANCER RESEARCH, INC. (THE "FOUNDATION") IS TO ENCOURAGE THE DEVELOPMENT OF MORE EFFECTIVE THERAPIES FOR PATIENTS WITH LEUKEMIA, LYMPHOMA AND RELATED CANCERS. THE FOUNDATION FUNDS INNOVATIVE CLINICAL OR BASIC SCIENCE RESEARCH THAT WILL LEAD TO NOVEL THERAPEUTIC APPROACHES THAT COULD REPLACE, OR BE USED IN COMBINATION WITH, EXISTING EFFECTIVE THERAPIES. SUCH THERAPEUTIC APPROACHES COULD INCLUDE INTEGRATIVE (INTEGRATIVE / COMPLEMENTARY) MEDICINE. THE FOUNDATION FUNDS RESEARCH TO IMPROVE THE EFFICENCY OF CANCER TREATMENTS, REDUCE THEIR TOXICITY AND IMPROVE THE QUALITY OF LIFE OF PATIENTS WITH LEUKEMIA OR LYMPHOMA. THE FOUNDATION ALSO SUPPORTS LIMITED SCIENTIFIC INTERCHANGE BETWEEN SELECT LEADERS IN DIFFERENT AREAS OF BIO AND INTEGRATIVE MEDICAL RESEARCH TO DEVELOP UNIQUE AND IMPORTANT COLLABORATIVE EFFORTS THAT WILL LEAD TO IMPROVEMENTS IN THE TREATMENT AND CARE OF PATIENTS WITH LEUKEMIA AND LYMPHOMA.

Activities or mission (Part I)

TO ENCOURAGE THE DEVELOPMENT OF MORE EFFECTIVE THERAPIES FOR PATIENTS WITH LEUKEMIA, LYMPHOMA

  • FOUNDATION FUNDS INNOVATIVE CLINICAL OR BASIC SCIENCE RESEARCH THAT WILL LEAD TO NOVEL THERAPEUTIC APPROACHES THAT COULD REPLACE, OR BE USED IN COMBINATION WITH EXISTING EFFECTIVE THERAPIES FOR PATIENTS WITH LEUKEMIA, LYMPHOMA AND RELATED CANCERS.

    Expenses $3,284,192 · Grants $2,703,500

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • DENISE RICH

    PRESIDENT & CO-FOUNDER

    Total calculated
    $0
    Hours/week
    3
  • BROOKE MILLSTEIN

    VICE CHAIR

    Total calculated
    $0
    Hours/week
    3
  • STAR JONES

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • PATRICIA QUICK

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • MICHELE RELLA

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • ILONA RICH SCHACHTER

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • THOMAS C QUICK

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • DANIELLA RICH KILSTOCK

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • PAUL SCHINDLER

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • LORRAINE E SCHWARTZ

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • STEPHEN D NIMER MD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • JENNIFER RANIERI

    EXECUTIVE DIRECTOR

    Total calculated
    $197,776
    From this org
    $197,776
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $170,650
    Bonus
    $27,126
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $197,776
  • MICHELE KEENE

    DIRECTOR OF DEVELOPMENT

    Total calculated
    $179,158
    From this org
    $179,158
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $123,955
    Bonus
    $55,203
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $179,158

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Form 990 of other organizations

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

The 10 largest by cash amount. The API serves every itemized grant.

Provenance

Return type
form_990
Tax year
2023
Filed
13 November 2024
IRS schema version
2023v5.1
Source object
202413189349311521

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.